A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
A phase 1/2 trial of DB-1324 in advanced solid tumours, run by DualityBio Inc., now recruiting.
Overview
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors is a phase 1/2 interventional study registered as NCT07263594 by DualityBio Inc., with 127 participants planned, started 2026-01-20 and due to reach its primary completion in 2028-12. Interventions recorded: DB-1324.
Similar pages
not linked directly; found by shared links- TrialFirst-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of DB-1310 in Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.